Get started

Nvaxshort

NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up. Novavax Reaches Settlement With Gavi, Paving The Way Forward In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations. The Dispute Resolution Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022. Impact On Novavax The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs. Settlement Terms Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark. Strategic Implications For Novavax The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company. Looking Ahead With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities. Conclusion In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
NASDAQ:NVAXLong
by realchartchamp
$NVAX Trending Back Down to the Buy ZoneNVAX has started distributing millions of COVID-19 vaccine shots. However, NVAX is trending back down towards the buy zone. I think that this will present a great second chance buy opportunity after NVAX's recent rally to $8. The markets have been affected by the new Israel Palestine conflict. Other key events this week are September PPI inflation data and Fed meeting minutes on Wednesday October 11. I think the markets are likely to have some sideways price action on Tuesday in anticipation of the new inflation and fed data.
NASDAQ:NVAXLong
by realchartchamp
2
NVAX - Novavax Biotech Short or not?NVAX as seen on the weekly chart has been in price distress for a long time. It has only one product on the market due to various issues with the FDA process. It has a variety of products in development as linked below. The question is whether it will run out of cash before a sustained revenue stream develops. FDA approvals for the pipeline products could take years ( the days of emergency approvals for COVID and related are over) It would seem that a rich uncle like Moderna ( MRNA) would codcme around with a take-over offer that could send shares into a moonshot to back when NVAX thrived before its 95% price decline in the past two years. This seems to be a great short swing play until more products come to market or a take-over is announced. This is affirmed by the MACD histogram being persistently negative for the long-term.
NASDAQ:NVAXShort
by AwesomeAvani
1
Novavax in a bear flag.Novavax - 30d expiry - We look to Sell a break of 15.49 (stop at 17.01) Daily signals are bearish. There is no clear indication that the downward move is coming to an end. Prices are extending lower from the bearish flag/pennant formation. Posted a bearish Flag formation. A break of 15.50 is needed to confirm the outlook. The bias is to break to the downside. This stock has seen poor sales growth. Our outlook is bearish. Our profit targets will be 12.12 and 11.62 Resistance: 18.00 / 18.55 / 19.50 Support: 16.30 / 15.53 / 15.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:NVAXShort
by Saxo
4